国药一致(000028) - 2024 Q1 - 季度财报

Financial Performance - The net profit attributable to the parent company decreased by 41.85%, amounting to a reduction of 41.2731 million yuan, primarily due to the decline in net profit from the subsidiary Guoyao Holdings Guoda Pharmacy Co., Ltd. [3] - The company achieved operating revenue of 19.09 billion yuan, a year-on-year increase of 2.16%[27] - Operating profit was 544 million yuan, a decrease of 5.61% compared to the previous year[27] - Total profit amounted to 550 million yuan, down 4.88% year-on-year[27] - Net profit reached 446 million yuan, a decline of 3.19% year-on-year[27] - Net profit attributable to shareholders of the listed company was 389 million yuan, an increase of 7.33% year-on-year[27] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 370 million yuan, up 5.10% year-on-year[27] Assets and Liabilities - The total assets increased from 36.37 billion yuan at the beginning of the period to 40.06 billion yuan at the end of the period, reflecting a growth of approximately 10.5% [18]. - Total assets amounted to 51.52 billion yuan, compared to 47.57 billion yuan in the previous period[20] - Total liabilities were 30.11 billion yuan, an increase from 26.59 billion yuan in the previous period[20] - The total liabilities increased by 22.38239 million yuan, reflecting a growth rate of 34.50%, primarily due to increased repayments of maturing loans during the period [13]. - Short-term borrowings increased by 1.19 billion yuan, representing a growth rate of 45.65%[30] Cash Flow - The cash and cash equivalents decreased by 62.5459 million yuan, showing a significant decline of 1,071.56%, mainly due to increased cash payments for goods purchased and slower collection of accounts receivable [13]. - The net cash flow from operating activities is negative CNY 634,145,768.90, a significant decrease of 402.00% compared to a positive CNY 209,985,468.33 in the same period last year[56] - Cash received from investment recoveries increased by ¥1,530.14 million, a staggering growth rate of 2,016.09% year-on-year[31] - Cash received from borrowings rose by ¥160.20 million, a growth rate of 40.29% compared to the previous year[33] - Cash paid for debt repayment increased by ¥313.57 million, a significant rise of 182.53% year-on-year[33] - The net cash flow from investing activities is negative CNY 51,986,965.23, an improvement from negative CNY 69,033,448.77 in the previous year[51] - The net cash flow from financing activities is positive CNY 119,039,993.93, compared to negative CNY 82,583,637.41 in the same period last year[51] Shareholder Information - The total number of common shareholders at the end of the reporting period was 32,682[71] - The largest shareholder, China National Pharmaceutical Group Corporation, holds 56.06% of shares, totaling 311,999,988 shares[71] - The second-largest shareholder, Industrial and Commercial Bank of China, holds 2.75% of shares, totaling 15,310,263 shares[71] - The fourth-largest shareholder, China Medical Import and Export Corporation, holds 1.24% of shares, totaling 6,919,956 shares[71] Research and Development - R&D expenses increased significantly to ¥6,260,235.43, a growth of 180.00% compared to ¥2,229,800.69 in the previous year[40] - The company's R&D expenses increased by CNY 4,030,400, representing a growth rate of 180.75% due to higher investment in research and development[60] Government Subsidies and Other Income - The company reported a government subsidy of 10.8889 million yuan, which is primarily related to various special subsidies and tax refunds received during the period [10]. - The investment income received increased by 842.53 million yuan, representing a staggering growth rate of 3,117.10%, attributed to increased dividends from the Guoyao Zhongjin Medical Industry Fund project [12]. - The asset disposal income increased by 1.2312 million yuan, with a growth rate of 69.31%, primarily due to the disposal gains from the rights of use assets related to retail store lease terminations [12]. Operational Changes - The company is focusing on optimizing financing structures and expanding market presence through strategic investments and partnerships[39] - The company plans to increase its share capital by 128,438,094 shares through a capital reserve distribution, adjusting the basic earnings per share from 0.85 yuan to 0.65 yuan for the previous year [8]. - Operating income increased by 4.7136 million yuan, with a growth rate of 137.14%, mainly due to the write-off of payables that do not need to be paid[69] - Cash inflow from other operating activities decreased by 171.9915 million yuan, showing a decline of 57.29%, mainly due to reduced receipts from reserve funds, deposits, and guarantees [12].